
<DOC>
<DOCNO>WT02-B10-8</DOCNO>
<DOCOLDNO>IA038-000728-B004-128</DOCOLDNO>
<DOCHDR>
http://www.deprenyl.com:80/Timeline.htm 208.129.179.70 19970111075737 text/html 9732
HTTP/1.0 200 OK
Server: Microsoft-IIS/2.0
Date: Sat, 11 Jan 1997 07:57:20 GMT
Content-Type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//W3O/DTD HTML//EN">

<html>
<head>
<title>DAHI Timeline</title>
<meta name="GENERATOR" content="Microsoft FrontPage 1.1">
<meta name="FORMATTER" content="Microsoft FrontPage 1.1">
</head>
<body background="images/Paper12l.jpg" bgcolor="#FFFFFF"
text="#000000" link="#FF0000" vlink="#400080" alink="#FFFF00">
<h1 align="center">A Timeline of Innovation</h1>
<hr>
<p align="center"><em><strong>Milestones in the history of DAHI
&amp; the Anipryl</strong></em><sup><font size="1"><em><strong>&#174;</strong></em></font></sup><em><strong>
development program... we're advancing the practice of veterinary
medicine for the benefit of pets &amp; their owners.</strong></em></p>
<hr>
<table cellpadding="5" cellspacing="25" width="95%">
    <tr>
        <td>
        <h1><em>1996</em> </h1>
        </td>
        <td></td>
    </tr>
    <tr>
        <td align="right" valign="top"><em>November</em></td>
        <td>DAHI and Draxis shareholders approve Share Exchange
        Agreement. DAHI becomes a wholly-owned subsidiary of
        Draxis Health Inc.</td>
    </tr>
    <tr>
        <td align="right" valign="top"><em>July</em></td>
        <td>Draxis announces its intention to acquire the
        remaining shares of DAHI that it doesn't already own via
        share exchange -- shareholder votes are scheduled for
        November, 1996</td>
    </tr>
    <tr>
        <td align="right" valign="top"><em>June</em></td>
        <td>DAHI submits canine senility (cognitive dysfunction)
        data application to the Canadian Bureau of Veterinary
        Drugs</td>
    </tr>
    <tr>
        <td align="right" valign="top"><em>April</em></td>
        <td>DAHI completes first commercial shipment of Anipryl<sup><font
        size="1">&#174;</font></sup> to Canada</td>
    </tr>
    <tr>
        <td align="right" valign="top"><em>March</em></td>
        <td>DAHI obtains sixth U.S. patent covering Anipryl<sup><font
        size="1">&#174;</font></sup>: increased life expectancy
        in pet dogs</td>
    </tr>
    <tr>
        <td align="right" valign="top"><em>January</em></td>
        <td>DAHI/Draxis sign Canadian Distribution Agreement for
        Anipryl<sup><font size="1">&#174;</font></sup></td>
    </tr>
    <tr>
        <td width="20%">
        <h1><em>1995</em> </h1>
        </td>
        <td width="50%"></td>
    </tr>
    <tr>
        <td align="right" valign="top" width="20%"><em>December</em></td>
        <td width="50%">Letter of Intent with Draxis Health, Inc.
        for exclusive distribution of Anipryl<sup><font size="1">&#174;</font></sup>
        in Canada<sup><font size="1">*</font></sup> </td>
    </tr>
    <tr>
        <td align="right" valign="top" width="20%"><em>November</em></td>
        <td width="50%">European patent for Anipryl<sup><font
        size="1">&#174;</font></sup> therapy of canine cognitive
        dysfunction allowed </td>
    </tr>
    <tr>
        <td align="right" valign="top" width="20%"><em>October</em></td>
        <td width="50%">First regulatory approval for Anipryl<sup><font
        size="1">&#174;</font></sup>, from the Canadian Bureau of
        Veterinary Medicine, Health Protection Branch, for the
        treatment of canine Cushing's disease* </td>
    </tr>
    <tr>
        <td align="right" valign="top" width="20%"><em>September</em></td>
        <td width="50%">New Animal Drug Application filed with
        the Center for Veterinary Medicine, FDA: Anipryl<sup><font
        size="1">&#174;</font></sup> therapy for canine Cushing's
        disease* </td>
    </tr>
    <tr>
        <td align="right" valign="top" width="20%"><em>February</em></td>
        <td width="50%">European patent for Anipryl<sup><font
        size="1">&#174;</font></sup> therapy of canine Cushing's
        disease allowed* </td>
    </tr>
    <tr>
        <td width="20%">
        <h1><em>1994</em> </h1>
        </td>
        <td width="50%"></td>
    </tr>
    <tr>
        <td align="right" valign="top" width="20%"><em>October</em></td>
        <td width="50%">First New Drug Submission filed with
        Canadian Health Protection Branch: Anipryl<sup><font
        size="1">&#174;</font></sup> therapy for canine Cushing's
        disease* </td>
    </tr>
    <tr>
        <td align="right" valign="top"><em>June</em></td>
        <td>Pivotal clinical trial (Phase III equivalent) begins:
        canine Cushing's disease for FDA approval*</td>
    </tr>
    <tr>
        <td align="right" valign="top"><em>April</em></td>
        <td>Pivotal clinical trial (Phase III equivalent) begins:
        canine cognitive dysfunction*</td>
    </tr>
    <tr>
        <td align="right" valign="top" width="20%"><em>March</em></td>
        <td width="50%">$2.5 million private placement: Draxis
        Health, Inc.* </td>
    </tr>
    <tr>
        <td width="20%">
        <h1><em>1993</em> </h1>
        </td>
        <td width="50%"></td>
    </tr>
    <tr>
        <td align="right" valign="top" width="20%"><em>July</em></td>
        <td width="50%">Presentation of canine cognitive
        dysfunction clinical trial data before the American
        Veterinary Society of Animal Behavior*<sup><font size="1">&#134;</font></sup> </td>
    </tr>
    <tr>
        <td align="right" valign="top" width="20%"><em>June</em></td>
        <td width="50%">Final, statistically significant results
        from first major pilot clinical trial (Phase II
        equivalent) evaluating Anipryl<sup><font size="1">&#174;</font></sup>
        therapy in canine cognitive dysfunction syndrome
        announced </td>
    </tr>
    <tr>
        <td align="right" valign="top" width="20%"><em>May</em></td>
        <td width="50%">First presentation of Cushing's disease
        clinical data at the American College of Veterinary
        Internal Medicine annual<br>
        meeting<sup><font size="1">&#134;</font></sup> </td>
    </tr>
    <tr>
        <td align="right" valign="top" width="20%"><em>March</em></td>
        <td width="50%">Issuance of DAHI's second U.S. patent
        covering the use of Anipryl<sup><font size="1">&#174;</font></sup>
        in the management of canine Cushing's disease </td>
    </tr>
    <tr>
        <td width="20%">
        <h1><em>1992</em> </h1>
        </td>
        <td width="50%"></td>
    </tr>
    <tr>
        <td align="right" valign="top" width="20%"><em>October</em></td>
        <td width="50%">Major pilot studies begin: Cushing's
        disease and cognitive dysfunction syndrome* </td>
    </tr>
    <tr>
        <td align="right" valign="top" width="20%"><em>September</em></td>
        <td width="50%">First U.S. patent issued - cognitive
        dysfunction* </td>
    </tr>
    <tr>
        <td align="right" valign="top" width="20%"><em>August</em></td>
        <td width="50%">Immune system benefit of Anipryl<sup><font
        size="1">&#174;</font></sup> demonstrated in old dogs </td>
    </tr>
    <tr>
        <td align="right" valign="top" width="20%"><em>April</em></td>
        <td width="50%">Initial laboratory success in treating
        cognitive dysfunction syndrome with Anipryl<sup><font
        size="1">&#174;</font></sup> </td>
    </tr>
    <tr>
        <td align="right" valign="top"><em>March</em></td>
        <td>First success treating Cushing's disease with Anipryl<sup><font
        size="1">&#174;</font></sup> </td>
    </tr>
    <tr>
        <td>
        <h1><em>1991</em> </h1>
        </td>
        <td></td>
    </tr>
    <tr>
        <td align="right" valign="top"><em>December</em></td>
        <td>U.S. trademark Anipryl<sup><font size="1">&#174;</font></sup>
        issued </td>
    </tr>
    <tr>
        <td align="right" valign="top"><em>October</em></td>
        <td>First Cushing's disease trial in pet dogs -- Kansas
        State University</td>
    </tr>
    <tr>
        <td align="right" valign="top"><em>March</em></td>
        <td>Initial public offering (NASDAQ: DAHI) </td>
    </tr>
    <tr>
        <td>
        <h1><em>1990</em> </h1>
        </td>
        <td></td>
    </tr>
    <tr>
        <td align="right" valign="top"><em>December</em></td>
        <td>INADA filed at the U.S. FDA</td>
    </tr>
    <tr>
        <td align="right" valign="top"><em>July</em></td>
        <td>DAHI incorporated</td>
    </tr>
</table>
<p><font size="1">*<i>additional information available in the
DAHI press release packet</i></font><br>
<font size="1">&#134;<i>abstracts available from DAHI upon
request </i></font></p>
<hr>
<p align="center">[ <a href="index.htm" target="_top">DAHI Home
Page</a> | <a href="frmvettp.htm" target="_top">Veterinarians</a>
| <a href="frmowntp.htm" target="_top">Pet Owners</a> | <a
href="frminvtp.htm" target="_top">Investors</a> ]</p>
<p align="center">[ <a href="about.htm">About DAHI</a> | <a
href="contents.htm" target="_top">Contents</a> | <a
href="contacts.htm">Contacts</a> | <a href="Links.htm">Links</a>
| <a href="Press.htm">Press Releases</a> | <a href="request.htm">Request
for Information</a> ]</p>
<hr>
<p><font size="2"><em>Send comments to DAHI webmaster: </em></font><a
href="mailto:dahimaster@deprenyl.com"><font size="2"><em>dahimaster@deprenyl.com</em></font></a><font
size="2"><em><br>
Copyright &#169; 1996 </em>Deprenyl Animal Health, Inc.<em> All
rights reserved.<br>
Revised: December 17, 1996.</em></font></p>
</body>
</html>
</DOC>